Symbolbild · KI-generiert
4D Molecular Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
4D Molecular Therapeutics develops gene therapies based on optimised adeno-associated viruses (AAV) generated using a proprietary directed evolution platform (Therapeutic Vector Evolution). Its clinical pipeline includes programmes for ocular, pulmonary and cardiac diseases. The company aims to achieve improved tissue specificity and reduced immune responses compared with naturally occurring AAV vectors.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | FDMT | NASDAQ | 532 Mio. USD |
| Tectonic Therapeutic, Inc. | TECX | NASDAQ | 529 Mio. USD |
| Prime Medicine, Inc. | PRME | NASDAQ | 527 Mio. USD |
| Shattuck Labs, Inc. | STTK | NASDAQ | 542 Mio. USD |
| Cytek Biosciences, Inc. | CTKB | NASDAQ | 545 Mio. USD |
| OrthoPediatrics Corp. | KIDS | NASDAQ | 519 Mio. USD |
| Arvinas, Inc. | ARVN | NASDAQ | 518 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.